8-K: Sage Therapeutics' Dalzanemdor Fails Primary Endpoint in Phase 2 Parkinson's Disease Trial

Sage Therapeutics' dalzanemdor did not meet its primary endpoint in a Phase 2 trial for mild cognitive impairment in Parkinson's disease, but the company remains optimistic about ongoing trials for Huntington's and Alzheimer's diseases.

Summary

• Sage Therapeutics announced topline results from the Phase 2 PRECEDENT study of dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's disease.
• The study did not meet its primary endpoint, failing to show a statistically significant difference versus placebo on the WAIS-IV Coding Test score at Day 42.
• A total of 86 participants were enrolled and randomized in the double-blind, placebo-controlled study.
• Dalzanemdor was generally well-tolerated, with most treatment-emergent adverse events being mild to moderate.
• The company does not plan further development of dalzanemdor for Parkinson's disease based on these results.
• Topline data from Phase 2 studies in Huntington's disease and Alzheimer's disease are expected later this year.

Sentiment

Score: 3

Explanation: The document reports a failed clinical trial, which is a negative event for the company. While there are some positives, the overall tone is negative due to the primary endpoint not being met.

Positives

• Dalzanemdor was generally well-tolerated in the study, with no new safety signals observed.
• The majority of treatment-emergent adverse events were mild to moderate in severity.
• Sage Therapeutics is continuing to advance clinical programs for dalzanemdor in Huntington's and Alzheimer's diseases.

Negatives

• The PRECEDENT study did not meet its primary endpoint, failing to show a statistically significant difference versus placebo.
• The company has decided not to pursue further development of dalzanemdor for Parkinson's disease.
• Analyses did not suggest any meaningful differences versus placebo in other exploratory endpoints such as SCOPA-Cog.

Risks

• The negative results from the PRECEDENT study may indicate potential challenges for dalzanemdor in other neurodegenerative conditions.
• Ongoing clinical studies of dalzanemdor in Huntington's and Alzheimer's diseases may also yield negative results.
• Regulatory approvals for dalzanemdor are not guaranteed, even if clinical trials are successful.
• The company may encounter delays in the initiation, conduct, or completion of ongoing or future clinical trials.

Future Outlook

Sage Therapeutics expects to report topline data from Phase 2 studies of dalzanemdor in Huntington's disease and Alzheimer's disease later in 2024. The company remains focused on its mission of developing treatments for brain health disorders.

Management Comments

• Barry Greene, Chief Executive Officer at Sage Therapeutics, stated they are disappointed by the results of the Phase 2 PRECEDENT study.
• Management believes the underlying pathophysiology and symptomatology in Parkinson's disease is distinctive, and these results do not necessarily predict results with dalzanemdor in other neurodegenerative conditions.

Industry Context

The failure of dalzanemdor in Parkinson's disease highlights the challenges in developing effective treatments for neurodegenerative disorders. The company's focus on Huntington's and Alzheimer's diseases reflects the broader industry trend of targeting specific disease mechanisms.

Comparison to Industry Standards

• The failure of dalzanemdor to meet its primary endpoint in Parkinson's disease is a setback, as many companies struggle to develop effective treatments for cognitive impairment in neurodegenerative diseases.
• Other companies such as Biogen and Eisai have had mixed results in their Alzheimer's disease trials, highlighting the difficulty in this area.
• The success of dalzanemdor in Huntington's and Alzheimer's trials will be closely watched, as positive results could position Sage as a leader in this space.

Stakeholder Impact

• Shareholders may react negatively to the failed trial results.
• Patients with Parkinson's disease will not benefit from this particular drug.
• Employees may experience uncertainty due to the change in development plans.
• The company's reputation may be slightly impacted by the negative results.

Next Steps

• Sage will report topline data from the SURVEYOR Study in Huntington's disease in mid-2024.
• Sage will report topline data from the LIGHTWAVE Study in Alzheimer's disease and the DIMENSION Study in Huntington's disease in late 2024.

Key Dates

Keywords

Dalzanemdor, SAGE-718, Parkinson's Disease, Mild Cognitive Impairment, Clinical Trial, Phase 2, Neurodegenerative, Huntington's Disease, Alzheimer's Disease, Cognitive Impairment